ReviewNutrients2021
Cardiovascular Diseases of Developmental Origins: Preventive Aspects of Gut Microbiota-Targeted Therapy.
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Microbiota-targeted interventions and clinical implications for maternal-offspring health: An umbrella review of systematic reviews and meta-analyses of randomised controlled trials.Journal of global health · 2024Pooled it
- Scaling Up Postbiotics Production: A Prospective Review of Processes and Health Benefits.Probiotics and antimicrobial proteins · 2026Review
- Selected Genes Associated With CVD-Related Diseases, Pathways, and Nutrigenetics.Journal of lipid and atherosclerosis · 2026Review
- Antioxidants, Gut Microbiota, and Cardiovascular Programming: Unraveling a Triad of Early-Life Interactions.Antioxidants (Basel, Switzerland) · 2025Review
- Exploring nutraceutical approaches linking metabolic syndrome and cognitive impairment.iScience · 2025Review
- Animal Models for Studying Developmental Origins of Cardiovascular-Kidney-Metabolic Syndrome.Biomedicines · 2025Review
- Cross-generational mechanisms of maternal gut microbiota in modulating offspring autism spectrum disorder risk: from the gut-brain axis to translational challenges in precision interventions.Frontiers in aging neuroscience · 2025Review
- Exploring the effect of gut flora on atrial fibrillation based on epidemiological history.Frontiers in cardiovascular medicine · 2025Review
- Effects of Marine-Derived Components on Cardiovascular Disease Risk Factors and Gut Microbiota Diversity.Marine drugs · 2024Review
- Review
- The potential preventive effect of probiotics, prebiotics, and synbiotics on cardiovascular risk factors through modulation of gut microbiota: A review.Food science & nutrition · 2024Review
- Review
- AttGRU-HMSI: enhancing heart disease diagnosis using hybrid deep learning approach.Scientific reports · 2024Article
- Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?Advances in therapy · 2024Article
- Nutritional Approaches Targeting Gut Microbiota in Oxidative-Stress-Associated Metabolic Syndrome: Focus on Early Life Programming.Nutrients · 2024Review
- Probiotics and Prebiotics in Cardiovascular Diseases.Nutrients · 2023Article
- The NOS/NO System in Renal Programming and Reprogramming.Antioxidants (Basel, Switzerland) · 2023Review
- Inflammatory Response: A Crucial Way for Gut Microbes to Regulate Cardiovascular Diseases.Nutrients · 2023Review
- Remodeling of the gut microbiome byFrontiers in microbiology · 2023Article
- The role of the gut microbiota in health and cardiovascular diseases.Molecular biomedicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cardiovascular diseases (CVDs) can originate from early life. Accumulating evidence suggests that gut microbiota in early life is linked to CVDs in later life. Gut microbiota-targeted therapy has gained significant importance in recent decades for its health-promoting role in the prevention (rather than just treatment) of CVDs. Thus far, available gut microbiota-based treatment modalities used as reprogramming interventions include probiotics, prebiotics, and postbiotics. The purpose of this review is, first, to highlight current studies that link dysbiotic gut microbiota to the developmental origins of CVD. This is followed by a summary of the connections between the gut microbiota and CVD behind cardiovascular programming, such as short chain fatty acids (SCFAs) and their receptors, trimethylamine-N-oxide (TMAO), uremic toxins, and aryl hydrocarbon receptor (AhR), and the renin-angiotensin system (RAS). This review also presents an overview of how gut microbiota-targeted reprogramming interventions can prevent the developmental origins of CVD from animal studies. Overall, this review reveals that recent advances in gut microbiota-targeted therapy might provide the answers to reduce the global burden of CVDs. Still, additional studies will be needed to put research findings into practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.